Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P37802

UPID:
TAGL2_HUMAN

ALTERNATIVE NAMES:
Epididymis tissue protein Li 7e; SM22-alpha homolog

ALTERNATIVE UPACC:
P37802; E9KL39; Q5JRQ6; Q5JRQ7; Q6FGI1; Q9BUH5; Q9H4P0

BACKGROUND:
The protein Transgelin-2, with its aliases Epididymis tissue protein Li 7e and SM22-alpha homolog, plays a pivotal role in the cytoskeletal organization. This protein's function is integral to maintaining cellular integrity and facilitating various cellular processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Transgelin-2 holds promise for unveiling new therapeutic avenues. Given its critical role in cellular architecture and processes, targeting Transgelin-2 could lead to innovative treatments for diseases where cellular structure and function are compromised.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.